Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 16:45:101136.
doi: 10.1016/j.gore.2023.101136. eCollection 2023 Feb.

What to expect from paraneoplastic syndromes of the nervous system in uterine cancer: A review of the literature

Affiliations
Review

What to expect from paraneoplastic syndromes of the nervous system in uterine cancer: A review of the literature

Anna Svarna et al. Gynecol Oncol Rep. .

Abstract

Neurological paraneoplastic syndromes are a rare subgroup of diseases commonly related to neuroendocrine tumors. However, they have been associated with uterine malignancies (sarcomas, endometrial carcinomas, and neuroendocrine cancers). Their presentation often correlates with a cancer diagnosis or cancer recurrence underlining their clinical significance. The most common neurological paraneoplastic syndrome in uterine cancer is cerebral degeneration with a comprehensive clinical presentation of pancerebral dysfunction. However, other neurological syndromes present with various symptoms leading to delayed diagnosis. Less common paraneoplastic neurological syndromes associated with uterine cancer are encephalitis, encephalomyelitis, subacute sensory neuropathy, sensory-motor neuropathy, dermatomyositis, cancer-associated retinopathy, opsoclonus, Guillain-Barre syndrome, necrotizing myopathy, and stiff-person syndrome. Herein, we reviewed published cases of neurological paraneoplastic syndromes in uterine cancer in order to raise awareness of these rare syndromes. We recorded patients' clinical presentation, antibodies detected, treatment, and clinical outcomes.

Keywords: Cancer; Endometrial; Gynaecological; Neurological; Paraneoplastic syndrome; Uterine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Similar articles

Cited by

References

    1. Adamus G. Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy. Autoimmun. Rev. 2009;8(5):410–414. - PMC - PubMed
    1. Antoine J.C., Honnorat J., Camdessanché J.P., Magistris M., Absi L., Mosnier J.F., et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann. Neurol. 2001;49(2):214–221. - PubMed
    1. Armangué T., Sabater L., Torres-Vega E., Martínez-Hernández E., Ariño H., Petit-Pedrol M., et al. Clinical and immunological features of opsoclonus-myoclonus syndrome in the era of neuronal cell surface antibodies. JAMA Neurol. 2016;73(4):417–424. - PMC - PubMed
    1. Bartos A. Effective high-dose clonazepam treatment in two patients with opsoclonus and myoclonus: GABAergic hypothesis. Eur. Neurol. 2006;56(4):240–242. - PubMed
    1. Bataller L., Graus F., Saiz A., Vilchez J.J. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain. 2001;124(Pt 2):437–443. - PubMed

LinkOut - more resources